Health Care·Life Sciences Tools & Services·$6.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.04 | N/A | -20.00% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.04 | N/A | -20.00% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed caution regarding future performance. They highlighted ongoing challenges but did not provide detailed insights.
Management did not provide specific guidance for future quarters.
The company acknowledged challenges in meeting expectations.
Repligen Corp's earnings report shows a miss on EPS, which likely contributed to the stock's decline of 5.08%. Investors may be concerned about the lack of guidance and management's cautious tone, indicating potential challenges ahead. The absence of revenue figures adds to the uncertainty surrounding the company's performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SYSCO CORP
Nov 3, 2014